Research Progress on Mechanism of Tumor-Associated Immune Thrombocytopenia
10.3971/j.issn.1000-8578.2025.25.0296
- VernacularTitle:肿瘤相关免疫性血小板减少的机制研究进展
- Author:
Guimin LIU
1
;
Huimin ZHU
2
;
Zhiyong CHENG
1
;
Wei QIN
3
Author Information
1. Department of Hematology, Baoding No.1 Hospital, Baoding 071000, China.
2. Department of Hematology, Baoding No.1 Hospital, Baoding 071000, China;Graduate School of Hebei North University, Zhangjiakou 075000, China.
3. Department of Hematology and Endocrinology, The 82nd Army Hospital of the Chinese People’s Liberation Army, Baoding 071000, China.
- Publication Type:REVIEWS
- Keywords:
Immune thrombocytopenia;
Tumor;
Mechanism;
Treatment
- From:
Cancer Research on Prevention and Treatment
2025;52(10):869-874
- CountryChina
- Language:Chinese
-
Abstract:
Thrombocytopenia is a common complication during the treatment of malignant tumors. It can lead to insufficient doses of chemotherapy drugs or delayed chemotherapy, shorten patients’ survival time, and affect prognosis. Thrombocytopenia has two types: cancer treatment-induced thrombocytopenia and tumor-associated immune thrombocytopenia. The latter is relatively rare, and its pathogenesis may be related to immune dysregulation. Current studies have shown that gene polymorphism and methylation are involved in tumor-associated immune thrombocytopenia. The pathogenesis and treatment of tumor-associated immune thrombocytopenia are discussed in this article.
